2 April 2021

A research group from Radboudumc and UMC Utrecht is to investigate laser treatment of a rare brain tumor, glioblastoma. 3.9 million euros has been made available for the research by Zorginstituut Nederland and ZonMw, under the auspices of the Subsidy Scheme for Promising Care.

The research group, which includes technical physician Kristian Overduin, professor of Health Evidence Maroeska Rovers, associate professor of Health Evidence Janneke Grutters, neurosurgeon Mark ter Laan of the Radboudumc, and neurosurgeon Pieter van Eijsden of UMC Utrecht, will receive 3.9 million euros for research into brain tumors. In the Netherlands, 1,100 people contract glioblastoma, a rare malignant brain tumor, each year. This is a brain tumor in which the average life span after diagnosis is up to two years. In thirty percent of patients, the tumor cannot be removed with surgery.  "With Stereotactic Laser Ablation (SLA), we can offer these patients a new option," said Radboudumc neurosurgeon Mark ter Laan, who is leading the study. "This is a minimally invasive surgery that allows the targeted burning away of brain tumors with laser light. The procedure takes place in an MRI scanner." The surgeon thus has direct images of the brain tumor during the treatment, preventing damage to surrounding tissue with important functions. Research abroad shows hopeful results.

Neurosurgeon Pieter van Eijsden of UMC Utrecht: "Because brain tumors are quite exceptional, relatively little is invested in this research compared to other tumors. That makes this award extra special." The Radboudumc and UMC Utrecht will now investigate the effect, complications and costs of this treatment for the first time in the Netherlands, supported by the National Neuro-Oncology Working Group and the patient association hersenletsel.nl. Also the effect on survival and quality of life will be investigated. The study should show whether SLA is indeed a better treatment for patients with glioblastoma where surgery is not possible.

 

Related news items


Patients who are obese or overweight are at risk for a more severe course of COVID-19

19 April 2021

International study shows risk of mortality does not increase

read more

New way of diagnostics detects 'undetectable' genetic defects

15 April 2021

Research provides guidance for global application

read more

Vici grant for Michiel Vermeulen Reading the epitranscriptome

15 April 2021

Michiel Vermeulen, theme Cancer development and immune defense, has been awarded a Vici grant from the Netherlands Organisation for Scientific Research (NWO), one of the largest personal scientific awards in the Netherlands.

read more

2.5 million Euros for cancer research into ovarian cancer and immunotherapy

15 April 2021

The Radboudumc receives 2.5 million Euros from the Dutch Cancer Society (KWF) for three studies to ensure oncological progress during COVID-19 period.

read more

COVID-19 regulations for nursing homes have varying effects

14 April 2021

On May 11th 2020, the Dutch Government allowed 26 nursing homes to welcome one visitor per resident, after two months of lockdown. An in-depth Radboudumc study monitored the feasibility of the regulations and the impact on the well-being of residents, their visitors, and healthcare staff.

read more